DrugDashboards

Brompheniramine, Pseudoephedrine, Dextromethorphan

Brompheniramine, Pseudoephedrine, Dextromethorphan · BROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL · Syrup · Oral · Ascend Laboratories, LLC

NDC 67877-0558-16 · 473 mL in 1 BOTTLE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.025$0.05$0.075Sep 2026Sep 2026$0.0714
1 price point · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$83.35
Reported to Texas DSHS · 2024 annual filing · Ascend Laboratories LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for brompheniramine, pseudoephedrine, dextromethorphan (other) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA210647
TE code
AA
Approval date
Jul 14, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Brompheniramine, Pseudoephedrine, Dextromethorphan (Syrup)

LabelerStrengthFirst seenLast seen
Ascend Laboratories, LLCBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mLAug 26, 2026Sep 2, 2026
Ascend Laboratories, LLCBROMPHENIRAMINE MALEATE 2 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 10 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 30 mg/5mLJul 22, 2026Aug 19, 2026
Ascend Laboratories, LLCBROMPHENIRAMINE MALEATE 2 mg/5mL; DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; PSEUDOEPHEDRINE HYDROCHLORIDE 30 mg/5mLJul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brompheniramine, Pseudoephedrine, Dextromethorphan — NDC 67877-0558-16," retrieved September 3, 2026, https://drugdashboards.com/drug/67877055816.

Free to cite with attribution — see how the data is put together.